Clinical Trials Browser

Bilateral Breast Carcinoma × Standard of Care × 90 days × Clear all

NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

Phase 2 Active not recruiting

Bilateral Breast Carcinoma